Mineralys Therapeutics, Inc. (MLYS) Tops Q2 EPS by 40c

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) reported Q2 EPS of ($0.66), $0.40 better than the analyst estimate of ($1.06).

For earnings history and earnings-related data on Mineralys Therapeutics, Inc. (MLYS) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Microsoft (MSFT) spreader of 2800 contracts of October 455 puts and October 490 calls
• Western Digital (WDC) call put ratio 1 call to 1 put as share price down 1.3%